Guest editorial: prophylaxis and treatment of relapse after allogeneic hematopoietic stem cell transplantation
Guest editorial: prophylaxis and treatment of relapse after allogeneic hematopoietic stem cell transplantation
复制标题
客座社论：异基因造血干细胞移植后复发的预防和治疗
DOI：
10.1007/s12185-022-03407-8
复制
发表时间：
2022
影响因子：
2.1
通讯作者：
Hashimoto Daigo
中科院分区：
文献类型：
--
作者：
井上 舞;川村 飛翔;佐川 展子;蒲原 毅;石井 文人;橋本 隆;Hashimoto Daigo
异基因造血干细胞移植（allo-HSCT）是恶性血液病（如白血病和淋巴瘤）的治愈性治疗选择。然而，复发仍然是移植后死亡的主要原因。为了治愈allo-HSCT后复发的恶性血液病，必须利用新的分子靶向治疗和/或免疫介导的抗白血病作用。近年来，多种分子靶向疗法和新型免疫疗法被开发用于治疗白血病和淋巴瘤。本期“血液学进展”包括四篇优秀的综述文章，总结了allo-HSCT后白血病/淋巴瘤复发的治疗和预防的最新进展。这些评论强调了新的免疫调节策略和分子靶向药物和传统的供体淋巴细胞输注（DLI）和第二次移植的作用。FLT 3内部串联重复（FLT 3-ITD）是成人急性髓性白血病（AML）中最常见的突变，并与预后不良相关[1]。Biavasco等人的综述讨论了FLT 3抑制剂在预防或治疗allo-HSCT后FLT 3突变的复发性AML复发中的作用。作者小组先前证明，索拉非尼（一种具有广泛脱靶活性的FLT 3抑制剂）刺激FLT 3突变白血病细胞产生IL-15，并通过增加具有细胞毒性和寿命特征的供体CD 8 + T细胞来增强GVL效应[2]。临床试验表明，索拉非尼维持治疗可降低FLT 3突变的复发风险。
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment option for hematological malignancies, such as leukemia and lymphoma. However, relapse remains the major cause of death after transplantation. To cure relapsed hematological malignancies after allo-HSCT, it is essential to utilize novel molecular-targeted therapies and/or immune-mediated antileukemia effects. Recently, multiple molecular-targeted therapies and novel immunotherapies have been developed to treat leukemia and lymphoma. This issue of ‘‘Progress in Hematology’’includes four excellent review articles that summarize the latest advances in the treatment and prophylaxis of leukemia/lymphoma relapse after allo-HSCT. These reviews highlight the role of novel immune-modulating strategies and molecular-targeted agents and conventional donor lymphocyte infusion (DLI) and second transplantation. FLT3 internal tandem duplication (FLT3-ITD) is the most frequent mutation in adult acute myeloid leukemia (AML) and is associated with a dismal prognosis [1]. The review by Biavasco et al. discusses the role of FLT3 inhibitors in prophylaxis or the treatment of FLT3-mutated relapsed AML relapse after allo-HSCT. The authors’ group previously demonstrated that sorafenib, an FLT3 inhibitor with broad off-target activities, stimulates IL-15 production from FLT3-mutated leukemia cells and enhances GVL effects by increasing donor CD8+ T cells with features of cytotoxicity and longevity [2]. Clinical trials showed that sorafenib maintenance reduces the risk for relapse of FLT3-mutated
影响因子：
45.3
作者：
Burchert, Andreas;Bug, Gesine;Metzelder, Stephan K.
通讯作者：
Metzelder, Stephan K.